Literature DB >> 11697339

Is hydroxyurea leukemogenic in children with sickle cell disease?

M de Montalembert, S C Davies.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11697339     DOI： 10.1182/blood.v98.9.2878

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  6 in total

1.  Occurrence of acute myeloid leukemia in hydroxyurea-treated sickle cell disease patient.

Authors:  Samuel Regan; Xuebin Yang; Niklas K Finnberg; Wafik S El-Deiry; Jeffrey J Pu
Journal:  Cancer Biol Ther       Date:  2019-08-18       Impact factor: 4.742

2.  The effect of hydroxyurea on vasculopathy in a child with sickle cell disease.

Authors:  Kathleen J Helton; Winfred C Wang; Lynn W Wynn; Raja B Khan; R Grant Steen
Journal:  AJNR Am J Neuroradiol       Date:  2002 Nov-Dec       Impact factor: 3.825

Review 3.  How I use hydroxyurea to treat young patients with sickle cell anemia.

Authors:  Russell E Ware
Journal:  Blood       Date:  2010-03-11       Impact factor: 22.113

4.  The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design.

Authors:  Bruce W Thompson; Scott T Miller; Zora R Rogers; Renee C Rees; Russell E Ware; Myron A Waclawiw; Rathi V Iyer; James F Casella; Lori Luchtman-Jones; Sohail Rana; Courtney D Thornburg; Ram V Kalpatthi; Julio C Barredo; R Clark Brown; Sharada Sarnaik; Thomas H Howard; Lori Luck; Winfred C Wang
Journal:  Pediatr Blood Cancer       Date:  2010-02       Impact factor: 3.167

5.  Myocardial ischaemia in children with sickle cell disease.

Authors:  M de Montalembert; C Maunoury; P Acar; V Brousse; D Sidi; G Lenoir
Journal:  Arch Dis Child       Date:  2004-04       Impact factor: 3.791

6.  Role of hydroxycarbamide in prevention of complications in patients with sickle cell disease.

Authors:  Nm Wiles; J Howard
Journal:  Ther Clin Risk Manag       Date:  2009-09-24       Impact factor: 2.423
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.